Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.170 +0.430 (+11.50%)

Delayed Quote Updated: 2:47 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Recursion Pharmaceuticals Earnings Preview ↗

August 04, 2025

Via Benzinga

2 Beaten-Down Stocks With Incredible Upside Potential ↗

August 03, 2025

Getting in on the ground floor with these companies might lead to superior returns.

Via The Motley Fool

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

July 29, 2025

Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST

From Recursion Pharmaceuticals

Via GlobeNewswire

Why Recursion Pharmaceuticals Stock Got Mashed on Monday ↗

July 28, 2025

Investors weren't cheered by news from one of the biotech's rivals.

Via The Motley Fool

The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. ↗

July 26, 2025

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

Via The Motley Fool

Topics Artificial Intelligence Retirement

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 08, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

Via Benzinga

Topics Artificial Intelligence ETFs

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma ↗

July 25, 2025

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

Via Benzinga

3 AI Stocks Partnered With Nvidia With Massive Growth Opportunities ↗

July 23, 2025

Via The Motley Fool

Topics Artificial Intelligence

Biocomputers: The Future of Computing is Alive

July 22, 2025

In the rapidly evolving world of technology, a groundbreaking frontier is emerging that could redefine the very nature of computation: biocomputers. Unlike traditional computers built from...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Recursion Pharmaceuticals Sees Sharp Gain on AI Biotech Optimism

July 22, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) experienced a notable surge in its stock price as investor enthusiasm for artificial intelligence-driven biotechnology reached new highs. The rally comes...

Via MarketMinute

Topics Artificial Intelligence

Top 2 Health Care Stocks You May Want To Dump This Quarter ↗

July 22, 2025

Via Benzinga

History of Recursion Pharmaceuticals, Inc.: AI‑Driven Drug Discovery Beginnings (NASDAQ:RXRX)

July 21, 2025

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) emerged in the 2010s as one of the pioneers in leveraging artificial intelligence (AI) and advanced data analytics to transform drug discovery and...

Via MarketMinute

Topics Artificial Intelligence

Is Recursion Pharmaceuticals Gaining or Losing Market Support? ↗

July 21, 2025

Via Benzinga

Why Is Recursion Pharma Stock Surging On Monday? ↗

July 21, 2025

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

Via Benzinga

Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday ↗

July 21, 2025

Via Benzinga

Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch. ↗

July 12, 2025

Via The Motley Fool

Topics Artificial Intelligence Initial Public Offering Intellectual Property

10 Under-the-Radar Tech Stocks With Incredible Growth Potential ↗

July 09, 2025

Just because it's not a household name doesn't mean it's not a magnificent investment.

Via The Motley Fool

Topics Artificial Intelligence

Here's Why Shares in Recursion Pharmaceuticals Surged Today ↗

July 08, 2025

Via The Motley Fool

Microchip Technology, Tesla, Humacyte And Other Big Stocks Moving Higher On Tuesday ↗

July 08, 2025

Via Benzinga

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? ↗

July 08, 2025

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and milestone payments.

Via Benzinga

The Hottest 10 Artificial Intelligence (AI) Stocks on the Market ↗

July 08, 2025

This group of companies reflects most of the industry's past, present, and future.

Via The Motley Fool

Topics Artificial Intelligence

Doctors Are Being Outpaced by AI-Powered Algorithms — Here’s What It Means for Investors

July 07, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:MSFT),(NASDAQ:ASTH),(NASDAQ:RXRX),(NASDAQ:MDAI) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Fraud

Alphabet-Backed Drug Discovery Firm Nears Human Trials Of AI-Developed Remedies, Says President: 'The Next Big Milestone Is...' ↗

July 07, 2025

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.

Via Benzinga

Topics Artificial Intelligence

What Analysts Are Saying About Recursion Pharmaceuticals Stock ↗

July 03, 2025

Via Benzinga

Is the Market Bullish or Bearish on Recursion Pharmaceuticals? ↗

June 26, 2025

Via Benzinga

Capital Flows Shift From Research Labs to Pharmacy Counters-A Watershed Moment for AI Health

June 17, 2025

Issued on behalf of Avant Technologies Inc. Vancouver, BC – June 17, 2025 – USA News Commentary – Momentum continues to build behind AI in healthcare, as capital finds its way to technologies capable...

Via FinancialNewsMedia

Topics Artificial Intelligence

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts ↗

June 16, 2025

Via Benzinga

Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy? ↗

June 16, 2025

Via The Motley Fool

Topics Animal Testing Artificial Intelligence Intellectual Property

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday ↗

June 10, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.